IDEXX Q3 revenue $1.1B (+13%), EPS $3.40 (+21%); raises FY2025 guidance

IDEXX LABORATORIES INC /DE

2025-Q3 EPS reported $9.99 revenue$3,213,123,000

Revenue $1,105M (+13% reported, +12% organic); CAG Diagnostics recurring revenue +11% reported, +10% organic.
EPS $3.40 (+21% reported, +15% comparable); operating margin 32.1%, +100 bps reported.
Raises FY2025 revenue guidance to $4,270-$4,300M (midpoint +$43M) and EPS guidance to $12.81-$13.01 (midpoint +$0.33).
Over 1,700 IDEXX inVue Dx placements in Q3; strong capital instrument revenue growth of 74% reported.
Updated FY2025 organic revenue growth outlook 8.8%-9.5%; comparable margin expansion guidance raised to 80-100 bps.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.